OXFORD BIOTHERAPEUTICS LTD

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +15.4%

  £17,973,731 → £20,747,184

• Cash

  -51.7%

  £9,852,718 → £4,757,244

  lowest in 3 filed years

• Net assets

  +228.4%

  -£1,615,724 → £2,075,035

  highest in 3 filed years

• Employees

  -6.5%

  46 → 43

• Operating profit

  +190.8%

  -£2,817,150 → £2,558,516

• Profit before tax

  +190.2%

  -£2,819,149 → £2,543,310

• Wages

  0%

  £5,337,144 → £5,337,530

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. OXFORD BIOTHERAPEUTICS LTD 2008-11-26 → present
2. OXFORD GENOME SCIENCES (UK) LIMITED 2003-12-19 → 2008-11-26
3. GW 1155 LIMITED 2003-11-24 → 2003-12-19

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

FLB Audit LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The financial statements have been prepared on the going concern basis which the Directors believe to be appropriate as set out below. In determining the appropriate basis of preparation of the financial statements for the year ended 31 December 2024, the Directors are required to consider whether the group can continue in operational existence for a period of at least 12 months from the approval of these financial statements ("going concern assessment period"). The Directors have prepared forecasts based on the pipeline of prospective and secured contracts and these forecasts indicate that the group will continue to meet its liabilities as they fall. Consequently, the directors are confident that the group will have sufficient funds to continue at least 12 months from the date of approval of the financial statements and therefore have prepared the financial statements on a going concern basis.”

Group structure

1. OXFORD BIOTHERAPEUTICS LTD · parent
   1. Oxford BioTherapeutics Inc. 100% · San Jose, CA 95138

Significant events

• “In February 2025, Oxford BioTherapeutics entered into a strategic collaboration with Roche to discover novel targets for antibody-based therapeutics for the treatment of cancer. This exciting new collaboration leverages OBT's proprietary OGAP®-Verify discovery platform and Roche's drug development expertise to advance multiple selected novel oncology targets. OBT is to receive up to US $36 million upfront payments and may be eligible to receive milestone payments potentially exceeding US $1 billion, as well as royalties.”
• “Longstanding collaborator Boehringer Ingelheim acquired a fourth license for the development of novel antibody-based cancer treatments for a target identified by OBT.”
• “OBT/Zymeworks collaboration: In October 2024 OBT entered into a strategic collaboration with Zymeworks to discover novel targets for antibody-based therapeutics for the treatment of cancer.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

3

last 12 months

Capital events

4

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.